These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31385522)

  • 1. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
    Cavallari LH; Lee CR
    Future Cardiol; 2019 Jul; 15(4):251-254. PubMed ID: 31385522
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes and Sustainability of Using
    Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
    Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies.
    Cavallari LH; Lee CR; Franchi F; Keeley EC; Rossi JS; Thomas CD; Gong Y; McDonough CW; Starostik P; Al Saeed MJ; Been L; Kulick N; Malave J; Mulrenin IR; Nguyen AB; Terrell JN; Tillotson G; Beitelshees AL; Winterstein AG; Stouffer GA; Angiolillo DJ
    Clin Transl Sci; 2024 Aug; 17(8):e70004. PubMed ID: 39150361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
    Claassens DMF; Bergmeijer TO; Vos GJA; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Mahmoodi BK; Deneer VHM; Ten Berg JM
    Circ Cardiovasc Interv; 2021 Apr; 14(4):e009434. PubMed ID: 33722066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
    Coons JC; Stevenson JM; Patel A; Smith AJC; Prebehalla L; Empey PE
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221143246. PubMed ID: 36503270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
    Martin J; Williams AK; Klein MD; Sriramoju VB; Madan S; Rossi JS; Clarke M; Cicci JD; Cavallari LH; Weck KE; Stouffer GA; Lee CR
    Genet Med; 2020 Jan; 22(1):160-169. PubMed ID: 31316169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
    Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
    Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Implementation of
    Azzahhafi J; Broek WWAVD; Chan Pin Yin DRPP; Harmsze AM; van Schaik RHN; Ten Berg JM
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231210704. PubMed ID: 37899583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
    Shen DL; Wang B; Bai J; Han Q; Liu C; Huang XH; Zhang JY
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):232-6. PubMed ID: 26727381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
    Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
    J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.